Milenko Jovan TanasijevicMD, MBA
Dr. Tanasijevic is the Vice Chair for Clinical Pathology and Quality of the Pathology Department of the Brigham and Women’s Hospital (BWH) and Dana Farber Cancer Institute (DFCI), the Director of the BWH Clinical Laboratories and an Associate Professor of Pathology at Harvard Medical School. He oversees over forty licensed laboratory sites performing more than 6 MM tests annually. The BWH Clinical Laboratories were recently recognized by the Institute of Medicine’s Roundtable on Value and Science-Driven Health Care as an example of increased system efficiency through application of Clinical Lab Automation and LEAN Process Redesign.
Dr. Tanasijevic completed his residency training in Clinical Pathology at the Brigham and Women’s Hospital in 1993. He became the Director of the DFCI Clinical Laboratories in 1999 and of both the BWH and DFCI Clinical Laboratories in 2002. Dr. Tanasijevic’s research in the area of cardiac biomarkers, a collaboration with Dr. Eugene Braunwald’s TIMI clinical trial group, resulted in a worldwide adoption of cardiac troponin-I as the new gold standard for diagnosing and risk-stratifying patients with acute myocardial infarction (AMI) and prompting the redefinition of AMI by the European Society of Cardiology and the American College of Cardiology in 2000.